查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1401993

2030年糖尿病腎臟病的全球市場預測：按類型、診斷類型、治療、給藥途徑、配銷通路、最終用戶和地區進行分析

Diabetic Nephropathy Market Forecasts to 2030 - Global Analysis By Type, By Diagnosis Type, By Treatment, Route of Administration, Distribution Channel, End Users and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球糖尿病腎臟病市場規模為 27 億美元，預計到 2030 年將達到 41 億美元，預測期內複合年成長率為 5.8%。

糖尿病腎臟病是由糖尿病引起的腎臟疾病，其特徵是長期高血糖導致腎臟損傷。透過定期篩檢進行早期發現可以及時進行干預，包括改變生活方式和藥物治療，以預防或減緩進展並降低與晚期腎臟疾病相關的併發症的風險。

根據國際糖尿病聯盟 (IDF) 的數據，40% 的糖尿病患者在階段可能會出現腎衰竭。此外，大約80%的末期腎功能衰竭是由糖尿病和高血壓引起的。

提高意識和主動篩檢計劃

宣傳宣傳活動正在教育人們有關糖尿病相關腎臟併發症的風險，並增加接受定期篩檢以早期發現的人數。早期發現可以及時干預和管理，有可能減緩糖尿病腎臟病變的進展並減少併發症。主動篩檢不僅有助於改善患者的治療結果，還可以提高醫療保健系統在糖尿病腎臟病變管理方面的整體有效性。這項背景凸顯了預防性醫療保健措施的重要性，使個人能夠主動應對糖尿病腎臟病並促進更好的長期健康結果。

治療費用高

糖尿病腎臟病變的治療很複雜，需要藥物治療、改變生活方式，在嚴重的情況下還需要腎臟替代治療，導致高昂的醫療費用。與持續就診、藥物以及透析或腎臟移植的可能性相關的經濟負擔可能會限制獲得最佳治療，特別是對於那些無法負擔費用的人來說。這些財務障礙可能導致治療延遲或不充分，進而對患者的治療結果產生負面影響。

政府糖尿病管理舉措

隨著全球各國政府優先考慮公共衛生，旨在預防和管理糖尿病的舉措將直接使市場受益。支持宣傳宣傳活動、糖尿病教育和無障礙篩檢計畫的政策有助於糖尿病腎臟病患者的早期發現和介入。政府支持的醫療保健計劃和藥品津貼改善了患者獲得治療的機會，並創造了有利於市場成長的環境。醫療保健當局和製藥業在這些舉措上的合作不僅將解決糖尿病的社會負擔，還將創建一個框架來支持糖尿病腎臟病變管理解決方案的擴展。

與某些藥物相關的副作用

儘管藥物治療在糖尿病腎臟病變的治療中發揮重要作用，但藥物的潛在副作用可能導致患者焦慮、違規和停止治療。胃腸道紊亂、低血糖和腎臟併發症等副作用可能會損害患者的整體健康。這項威脅凸顯了開發和處方具有良好安全性的藥物的重要性。製藥公司和醫療保健提供者必須優先考慮研究和創新，以最大限度地減少副作用，並確保治療的好處大於潛在的風險。

COVID-19 的影響：

COVID-19 的爆發對糖尿病腎臟病市場產生了多方面的影響。醫療保健服務的中斷、患者不願尋求非緊急護理以及將資源轉移到流行病管理上，這些都共同影響了糖尿病腎臟病的診斷和管理。然而，這場大流行也強調了主動管理的重要性，並強調了遠端醫療和數位健康解決方案的機會，以加強糖尿病腎臟病變的遠端監測和患者照護。

尿液檢查領域預計將在預測期內成為最大的領域

尿液檢查領域預計將出現良好的成長。這些測試，例如蛋白尿和蛋白尿評估，可以幫助及早發現糖尿病引起的腎臟損傷。監測尿液中蛋白質水平是否異常有助於醫療專業人員評估腎臟病的進展。定期尿液檢查可以及時干預和個體化治療計劃，有助於更好地管理糖尿病腎臟病變並改善患者預後。它作為一種非侵入性、經濟高效的診斷工具，支持有效的醫療保健策略來對抗糖尿病併發症。

預計醫院業在預測期內複合年成長率最高。

預計醫院產業在預測期內將以最快的複合年成長率成長。這些醫療機構提供基本服務，例如診斷篩檢、腎臟病專家諮詢以及獲得各種治療性介入。該醫院也為重症病例提供透析和腎臟移植等更先進的治療。此外，該醫院也是病患教育中心，有助於提高人們對糖尿病腎臟病的認知和主動管理。醫院、醫療保健專業人員和患者之間的合作對於應對糖尿病腎臟病變帶來的挑戰和改善患者的治療效果至關重要。

佔有率最大的地區

預計北美市場在預測期內將繼續佔據大部分市場佔有率。該地區先進的醫學研究能力有助於早期檢測、創新治療方法和強勁的醫藥市場。政府措施、醫療保健政策和人們對糖尿病的認知不斷提高，進一步推動了市場成長。隨著高齡化和對預防保健的重視，北美在製定有效管理糖尿病腎臟病變的進展和解決方案方面繼續發揮關鍵作用。

複合年成長率最高的地區：

預計亞太地區在預測期內複合年成長率最高。該地區糖尿病盛行率不斷上升，特別是在中國和印度等國家，增加了對糖尿病腎臟病變管理的需求。政府舉措、改善的醫療基礎設施以及增加的研發投資都有助於市場的擴張。隨著該地區應對糖尿病流行，亞太地區糖尿病腎臟病市場出現了顯著成長，為醫療保健提供者和製藥公司提供了滿足人們不斷變化的醫療保健需求的機會。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球糖尿病腎臟病市場：依類型

  • 1型糖尿病
  • 2型糖尿病
  • 其他類型

第6章全球糖尿病腎臟病市場：依診斷類型

  • 驗血
  • 尿液檢查
  • 影像檢查
  • 腎功能檢查
  • 切片檢查
  • 其他診斷類型

第7章全球糖尿病腎臟病市場：依治療分類

  • 藥品
    • 利尿劑
    • 抗氧化發炎調節劑
    • 血管收縮素受體阻斷劑
    • 血管張力素轉化酵素抑制劑（ACE抑制劑）
    • 腎素抑制劑
    • 鈣離子通道阻斷劑
    • 其他藥品
  • 腎臟透析
  • 移植

第8章全球糖尿病腎臟病變市場：依給藥途徑

  • 口服
  • 家長
  • 其他給藥途徑

第9章全球糖尿病腎臟病變市場：依配銷通路

  • 線上藥房
  • 零售藥房

第 10 章全球糖尿病腎臟病市場：依最終用戶分類

  • 醫院
  • 居家護理
  • 專業中心
  • 其他最終用戶

第11章全球糖尿病腎臟病變市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第12章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章 公司簡介

  • F. Hoffmann-La Roche Ltd
  • Fresenius Kabi AG
  • GlaxoSmithKline Plc.
  • Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
  • Hikma Pharmaceuticals PLC
  • Mylan NV
  • Novartis AG
  • Pfizer Inc
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG
  • Bristol Myers Squibb Company
Product Code: SMRC24513

According to Stratistics MRC, the Global Diabetic Nephropathy Market is accounted for $2.7 billion in 2023 and is expected to reach $4.1 billion by 2030 growing at a CAGR of 5.8% during the forecast period. Diabetic Nephropathy is a kidney condition resulting from diabetes, characterized by kidney damage due to prolonged high blood sugar levels. Its early detection through regular screening allows for timely intervention, including lifestyle modifications and medications, preventing or slowing progression and reducing the risk of complications associated with advanced kidney disease.

According to the International Diabetes Federation (IDF), 40% of diabetics may experience kidney failure in its ultimate stages. Furthermore, about 80% of end-stage renal failure is caused by diabetes and hypertension, either together or individually.

Market Dynamics:

Driver:

Increased awareness and proactive screening programs

Awareness campaigns educate individuals about the risks of kidney complications associated with diabetes, more people are encouraged to undergo regular screenings for early detection. Early identification enables prompt intervention and management, potentially slowing the progression of diabetic nephropathy and reducing associated complications. Proactive screening not only contributes to better patient outcomes but also enhances the overall effectiveness of healthcare systems in managing diabetic nephropathy. This driver underscores the importance of preventive healthcare measures, empowering individuals to take proactive steps in addressing diabetic nephropathy and promoting better long-term health outcomes.

Restraint:

High treatment costs

The complex nature of managing diabetic nephropathy, which may involve medications, lifestyle modifications, and, in severe cases, renal replacement therapies, contributes to elevated healthcare expenses. The financial burden associated with consistent medical appointments, medications, and potential dialysis or kidney transplantation can limit access to optimal care, especially for individuals with limited financial resources. This economic barrier may result in delayed or inadequate treatment, adversely impacting patient outcomes.

Opportunity:

Government initiatives for diabetes management

As governments globally prioritize public health, initiatives aimed at preventing and managing diabetes directly benefit the market. Policies supporting awareness campaigns, diabetes education, and accessible screening programs contribute to early detection and intervention in diabetic nephropathy cases. Government-backed healthcare programs and subsidies for medications can enhance patient access to treatment, fostering a more conducive environment for market growth. Collaboration between healthcare authorities and the pharmaceutical industry to align with these initiatives not only addresses the societal burden of diabetes but also creates a supportive framework for the expansion of diabetic nephropathy management solutions.

Threat:

Side effects associated with certain medications

Pharmaceutical interventions play a crucial role in managing diabetic nephropathy, the potential adverse effects of medications may lead to patient apprehension, non-compliance, or discontinuation of treatment. Side effects such as gastrointestinal issues, hypoglycemia, and renal complications can compromise the overall well-being of patients. This threat underscores the importance of developing and prescribing medications with favorable safety profiles. Pharmaceutical companies and healthcare providers must prioritize research and innovation to minimize side effects, ensuring that the benefits of treatment outweigh potential risks.

COVID-19 Impact:

The COVID-19 pandemic has had a multifaceted impact on the Diabetic Nephropathy Market. Disruptions in healthcare services, patient hesitancy to seek non-urgent medical care, and diversion of resources to pandemic management have collectively affected the diagnosis and management of diabetic nephropathy. However, the pandemic has also emphasized the importance of proactive management and highlighted opportunities for telemedicine and digital health solutions to enhance remote monitoring and patient care in the diabetic nephropathy landscape.

The urine test segment is expected to be the largest during the forecast period

The urine test segment is expected to have a lucrative growth. These tests, such as albuminuria and proteinuria assessments, help in early detection of kidney damage caused by diabetes. Monitoring the presence of abnormal levels of proteins in the urine aids healthcare professionals in assessing the progression of nephropathy. Regular urine testing allows for timely intervention and personalized treatment plans, contributing to better management of diabetic nephropathy and improved patient outcomes. It serves as a non-invasive and cost-effective diagnostic tool, supporting effective healthcare strategies in combating this complication of diabetes.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is anticipated to witness the fastest CAGR growth during the forecast period. These healthcare institutions provide essential services, including diagnostic screenings, consultations with nephrologists, and access to a range of therapeutic interventions. Hospitals also facilitate more advanced treatments like dialysis and kidney transplantation for severe cases. Additionally, they serve as hubs for patient education, contributing to increased awareness and proactive management of diabetic nephropathy. The collaborative efforts of hospitals, healthcare professionals, and patients are critical in addressing the challenges posed by diabetic nephropathy and improving patient outcomes.

Region with largest share:

During the forecast period, it is expected that the North American market will continue to hold a majority of the market share. The region's advanced medical research capabilities contribute to early detection, innovative therapies, and a robust pharmaceutical market. Government initiatives, healthcare policies, and a heightened awareness of diabetes further support the market's growth. With a growing aging population and a focus on preventive healthcare, North America continues to be a key player in shaping advancements and solutions for the effective management of diabetic nephropathy.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period. The region's rising prevalence of diabetes, particularly in countries like China and India, amplifies the demand for diabetic nephropathy management. Government initiatives, improving healthcare infrastructure, and growing investments in research and development contribute to the market's expansion. As the region grapples with the diabetes epidemic, the Diabetic Nephropathy Market in Asia Pacific is positioned for substantial growth, presenting opportunities for healthcare providers and pharmaceutical companies to address the evolving healthcare needs of the population.

Key players in the market:

Some of the key players in Diabetic Nephropathy market include F. Hoffmann-La Roche Ltd, Fresenius Kabi AG, GlaxoSmithKline Plc., Hebei Changshan Biochemical Pharmaceutical Co. Ltd., Hikma Pharmaceuticals PLC, Mylan N.V., Novartis AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd., Bayer AG and Bristol Myers Squibb Company.

Key Developments:

In March 2023, Novartis announced that it had submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for renoprotective effects of sevelamer carbonate, a phosphate binder, for the treatment of diabetic nephropathy.

In January 2023, Boehringer Ingelheim and Eli Lilly and Company announced that US Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) investigating a potential new indication to lower blood sugar along with diet and exercise in children 10 years and older with type 2 diabetes. These tablets have been investigated as a possible therapy to reduce the chance of cardiovascular death and kidney disease progression in adults with chronic kidney disease.

In December 2022, Bayer launched Finerenone under the brand name Kerendia in India. Finerenone is a first-in-class non-steroidal, selective mineralocorticoid receptor antagonist indicated for patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).

Types Covered:

  • Type-1 Diabetes
  • Type-2 Diabetes
  • Other Types

Diagnosis Types Covered:

  • Blood Test
  • Urine Test
  • Imaging Test
  • Renal Function Testing
  • Kidney Biopsy
  • Other Diagnosis Types

Treatments Covered:

  • Medication
  • Kidney Dialysis
  • Transplant

Route of Administrations Covered:

  • Oral
  • Parental
  • Other Route of Administrations

Distribution Channels Covered:

  • Online Pharmacy
  • Retail Pharmacy

End Users Covered:

  • Hospitals
  • Homecare
  • Speciality Centres
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Diabetic Nephropathy Market, By Type

  • 5.1 Introduction
  • 5.2 Type-1 Diabetes
  • 5.3 Type-2 Diabetes
  • 5.4 Other Types

6 Global Diabetic Nephropathy Market, By Diagnosis Type

  • 6.1 Introduction
  • 6.2 Blood Test
  • 6.3 Urine Test
  • 6.4 Imaging Test
  • 6.5 Renal Function Testing
  • 6.6 Kidney Biopsy
  • 6.7 Other Diagnosis Types

7 Global Diabetic Nephropathy Market, By Treatment

  • 7.1 Introduction
  • 7.2 Medication
    • 7.2.1 Diuretics
    • 7.2.2 Antioxidant Inflammation Modulator
    • 7.2.3 Angiotensin Receptor Blockers
    • 7.2.4 Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
    • 7.2.5 Renin Inhibitors
    • 7.2.6 Calcium Channel Blockers
    • 7.2.7 Other Medications
  • 7.3 Kidney Dialysis
  • 7.4 Transplant

8 Global Diabetic Nephropathy Market, By Route of Administration

  • 8.1 Introduction
  • 8.2 Oral
  • 8.3 Parental
  • 8.4 Other Route of Administrations

9 Global Diabetic Nephropathy Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Online Pharmacy
  • 9.3 Retail Pharmacy

10 Global Diabetic Nephropathy Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Homecare
  • 10.4 Specialty Centers
  • 10.5 Other End Users

11 Global Diabetic Nephropathy Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 F. Hoffmann-La Roche Ltd
  • 13.2 Fresenius Kabi AG
  • 13.3 GlaxoSmithKline Plc.
  • 13.4 Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
  • 13.5 Hikma Pharmaceuticals PLC
  • 13.6 Mylan N.V.
  • 13.7 Novartis AG
  • 13.8 Pfizer Inc
  • 13.9 Teva Pharmaceutical Industries Ltd.
  • 13.10 Bayer AG
  • 13.11 Bristol Myers Squibb Company

List of Tables

  • Table 1 Global Diabetic Nephropathy Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Diabetic Nephropathy Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Diabetic Nephropathy Market Outlook, By Type-1 Diabetes (2021-2030) ($MN)
  • Table 4 Global Diabetic Nephropathy Market Outlook, By Type-2 Diabetes (2021-2030) ($MN)
  • Table 5 Global Diabetic Nephropathy Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 6 Global Diabetic Nephropathy Market Outlook, By Diagnosis Type (2021-2030) ($MN)
  • Table 7 Global Diabetic Nephropathy Market Outlook, By Blood Test (2021-2030) ($MN)
  • Table 8 Global Diabetic Nephropathy Market Outlook, By Urine Test (2021-2030) ($MN)
  • Table 9 Global Diabetic Nephropathy Market Outlook, By Imaging Test (2021-2030) ($MN)
  • Table 10 Global Diabetic Nephropathy Market Outlook, By Renal Function Testing (2021-2030) ($MN)
  • Table 11 Global Diabetic Nephropathy Market Outlook, By Kidney Biopsy (2021-2030) ($MN)
  • Table 12 Global Diabetic Nephropathy Market Outlook, By Other Diagnosis Types (2021-2030) ($MN)
  • Table 13 Global Diabetic Nephropathy Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 14 Global Diabetic Nephropathy Market Outlook, By Medication (2021-2030) ($MN)
  • Table 15 Global Diabetic Nephropathy Market Outlook, By Diuretics (2021-2030) ($MN)
  • Table 16 Global Diabetic Nephropathy Market Outlook, By Antioxidant Inflammation Modulator (2021-2030) ($MN)
  • Table 17 Global Diabetic Nephropathy Market Outlook, By Angiotensin Receptor Blockers (2021-2030) ($MN)
  • Table 18 Global Diabetic Nephropathy Market Outlook, By Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors) (2021-2030) ($MN)
  • Table 19 Global Diabetic Nephropathy Market Outlook, By Renin Inhibitors (2021-2030) ($MN)
  • Table 20 Global Diabetic Nephropathy Market Outlook, By Calcium Channel Blockers (2021-2030) ($MN)
  • Table 21 Global Diabetic Nephropathy Market Outlook, By Other Medications (2021-2030) ($MN)
  • Table 22 Global Diabetic Nephropathy Market Outlook, By Kidney Dialysis (2021-2030) ($MN)
  • Table 23 Global Diabetic Nephropathy Market Outlook, By Transplant (2021-2030) ($MN)
  • Table 24 Global Diabetic Nephropathy Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 25 Global Diabetic Nephropathy Market Outlook, By Oral (2021-2030) ($MN)
  • Table 26 Global Diabetic Nephropathy Market Outlook, By Parental (2021-2030) ($MN)
  • Table 27 Global Diabetic Nephropathy Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
  • Table 28 Global Diabetic Nephropathy Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 29 Global Diabetic Nephropathy Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 30 Global Diabetic Nephropathy Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 31 Global Diabetic Nephropathy Market Outlook, By End User (2021-2030) ($MN)
  • Table 32 Global Diabetic Nephropathy Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 33 Global Diabetic Nephropathy Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 34 Global Diabetic Nephropathy Market Outlook, By Specialty Centers (2021-2030) ($MN)
  • Table 35 Global Diabetic Nephropathy Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.